What is the mechanism of action of Furmonertinib and Furmonertinib? Furmonertinib is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor mainly used to treat non-small cell lung cancer. Its efficacy is as follows: 1. It is mainly used to treat non-small cell lung cancer patients with positive epidermal growth factor receptor gene mutations; 2. The mechanism of action is to target and inhibit EGFR tyrosine kinase activity, thereby blocking the signaling pathway for tumor cell growth and spread; 3. Used as a first-line treatment or as a follow-up treatment option after the failure of other EGFR inhibitors; This drug has shown excellent performance in clinical trials, with significant efficacy and high safety.
1.EGFR mutations and non-small cell lung cancer
EGFR is a membrane receptor tyrosine kinase that is involved in the growth and division of lung cancer cells. EGFR mutation is the most common molecular change in non-small cell lung cancer, accounting for approximately 30% to 40% of patients. These mutations lead to excessive activation of EGFR, which in turn promotes tumor growth and metastasis.
2. The mechanism of action of Fumatinib
Fumatinib is a highly selective EGFR mutation inhibitor, also known as the third-generation EGFR inhibitor. It blocks the binding between ATP and EGFR by binding to the ATP binding site on the EGFR protein, thereby inhibiting the tyrosine kinase activity of EGFR. This mechanism enables Fumatinib to effectively inhibit mutated EGFR, thereby blocking the proliferation and survival of tumor cells.
3. Advantages of Fumatinib
Compared with the first and second generation EGFR inhibitors, fumatinib is more effective in inhibiting mutated EGFR. It can reverse the resistance phenomenon that occurs in the treatment of many EGFR kinase inhibitors, such as gefitinib. In addition, Fumatinib has shown good efficacy in the treatment of non-small cell lung cancer with brain metastases, as it can better cross the blood-brain barrier.
4. The therapeutic application and side effects of Ivessa
Fumatinib and Efusa are administered orally to patients in tablet form. It is used to treat patients with EGFR mutation positive advanced or metastatic non-small cell lung cancer. There are also some side effects of using Fumatinib, including diarrhea, rash, hair loss, nausea, gastrointestinal inflammation, etc. Therefore, when using Fumatinib, patients need to closely monitor and consult with a doctor.
